Last reviewed · How we verify

Inactivated Split-virion influenza vaccine

Sanofi Pasteur, a Sanofi Company · Phase 3 active Biologic

Inactivated Split-virion influenza vaccine is a Inactivated viral vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently in Phase 3 development for Seasonal influenza prevention in adults and children. Also known as: Vaxigrip.

This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection.

This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection. Used for Seasonal influenza prevention in adults and children.

At a glance

Generic nameInactivated Split-virion influenza vaccine
Also known asVaxigrip
SponsorSanofi Pasteur, a Sanofi Company
Drug classInactivated viral vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The split-virion formulation contains disrupted influenza virus particles that present viral antigens to the immune system without causing infection. This triggers both humoral (antibody) and cellular immune responses, enabling the body to mount a rapid defense against subsequent exposure to circulating influenza strains. The inactivated nature ensures safety while maintaining immunogenicity.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Inactivated Split-virion influenza vaccine

What is Inactivated Split-virion influenza vaccine?

Inactivated Split-virion influenza vaccine is a Inactivated viral vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Seasonal influenza prevention in adults and children.

How does Inactivated Split-virion influenza vaccine work?

This vaccine stimulates the immune system to recognize and respond to inactivated influenza virus particles, providing protection against seasonal influenza infection.

What is Inactivated Split-virion influenza vaccine used for?

Inactivated Split-virion influenza vaccine is indicated for Seasonal influenza prevention in adults and children.

Who makes Inactivated Split-virion influenza vaccine?

Inactivated Split-virion influenza vaccine is developed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is Inactivated Split-virion influenza vaccine also known as anything else?

Inactivated Split-virion influenza vaccine is also known as Vaxigrip.

What drug class is Inactivated Split-virion influenza vaccine in?

Inactivated Split-virion influenza vaccine belongs to the Inactivated viral vaccine class. See all Inactivated viral vaccine drugs at /class/inactivated-viral-vaccine.

What development phase is Inactivated Split-virion influenza vaccine in?

Inactivated Split-virion influenza vaccine is in Phase 3.

What are the side effects of Inactivated Split-virion influenza vaccine?

Common side effects of Inactivated Split-virion influenza vaccine include Injection site soreness or erythema, Myalgia, Headache, Fatigue, Low-grade fever.

Related